TTOO - T2 Biosystems' T2SARS-CoV-2 Panel detects Omicron variant

T2 Biosystems (NASDAQ:TTOO) perks up 3.3% premarket after announcing that its T2SARS-CoV-2 Panel detects the Omicron COVID-19 variant (B.1.1.529). To confirm that the T2SARS-CoV-2 Panel would detect the new variant, in silico analysis was performed using sequences in the GISAID database. SARS-CoV-2 (B.1.1.529) sequences were evaluated for alignment with primer and probe sequences from T2SARS-CoV-2 Panel. These analyses demonstrated that none of the new B.1.1.529 mutations occur within the region targeted by the T2SARS-CoV-2 Panel. The T2SARS-CoV-2 Panel, which has demonstrated clinical sensitivity of 95% and specificity of 100%, provides results in under two hours utilizing an upper respiratory swab sample. The WHO has designated the Omicron variant as a “variant of concern” with more than 30 mutations in the spike protein region.

For further details see:

T2 Biosystems' T2SARS-CoV-2 Panel detects Omicron variant